COVID-19 Bivalent Vaccine Booster Approved

Last week the Advisory Committee on Immunization Practices (ACIP), with approval from the Centers for Disease Control and Prevention (CDC), recommended the updated Moderna and Pfizer-BioNTech bivalent COVID-19 boosters. These new “bivalent” vaccines are designed to fight the Omicron strains of COVID-19 more effectively.
Eligible individuals should wait at least two months after receiving their primary series or prior monovalent booster before receiving the bivalent booster. Individuals with a prior COVID-19 infection should wait three months from symptom onset or a positive test (if asymptomatic) before receiving the bivalent booster.  
The approval and recommendation to use the monovalent Pfizer-BioNTech COVID-19 boosters for persons aged 12 years and older and the monovalent Moderna COVID-19 booster for persons 18 and older are repealed and replaced with recommendations to use the updated bivalent vaccine. This means individuals do not need to choose which booster to receive as there is only one booster available; the bivalent is now the sole booster. 
The recommendations also confirmed that co-administration of the bivalent and influenza vaccine are allowed without contraindications. Therefore, providers should offer both influenza and COVID-19 vaccines during vaccine clinics if a person is eligible for both.
AHCA/NCAL has been meeting with the CDC and LTC pharmacy partners to ensure LTC remains a top priority for access to this booster. Facilities should contact their LTC pharmacies and schedule bivalent booster and influenza clinics for the coming months. 
Please contact with questions.

Staff Contact: